Predicting whether Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) or any individual biotechnology stock will rise is impossible, as share trajectories depend on unpredictable clinical trial outcomes, regulatory approvals, partnership announcements, and broader biotech sector trends. While positive clinical pipeline data or commercial milestone achievements can drive sharp upward momentum, clinical setbacks or regulatory delays can trigger sudden declines. Investors evaluating biotechnology equities should review comprehensive balance sheet health, upcoming drug catalyst timelines, and personal risk parameters.